Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance

Javier Molina-Infante, Javier P Gisbert

Abstract
The efficacy of triple therapy for Helicobacter pylori infection has dramatically declined over the last decade, largely related to increasing clarithromycin resistance rates. From a microbiological standpoint, bismuth quadruple therapy is the ideal replacement since it combines drugs for which resistance does not impair its efficacy. Nonetheless, several obstacles such as availability, complexity or tolerance prevent a general implementation of bismuth quadruple therapy, so non-bismuth quadruple regimens remain the best first-line treatment in clinical practice in many geographical areas. We review the rationale and efficacy of several optimization tools (increasing the length of treatment, high-dose acid suppression, probiotics), which have been largely evaluated over the last 5 years to increase the effectiveness of standard triple therapy. Then, we update available evidence on the effectiveness of several non-bismuth quadruple therapies (sequential, concomitant, hybrid, miscellaneous) that have gained interest lately. We also review evidence on the efficacy of the aforementioned optimization tools for non-bismuth quadruples schemes and, finally, we provide a novel regionalized therapeutic algorithm, based on novel formulas recently developed for predicting the outcome of non-bismuth quadruple regimens, upon local antibiotic resistance rates.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

Key words: Helicobacter pylori; Eradication; Clarithromycin; Sequential; Concomitant; Hybrid; Antibiotic resistance; Bismuth

Core tip: Triple therapy is no longer effective to eradicate Helicobacter pylori infection in most settings across the world. Bismuth quadruple therapy has resurfaced as an ideal replacement, despite its implementation in clinical practice may be troublesome. As such, non-bismuth quadruple therapies remain in the therapeutic front line in clinical practice. This article updates available evidence over the last five years on the efficacy of several non-bismuth quadruple schemes and different tools used to optimize them, providing a novel regionalized therapeutic algorithm, according to novel predicting models based on local antibiotic resistance rates.

Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol 2014; 20(30): 10338-10347 Available from: URL: http://www.wjgnet.com/1007-9327/full/v20/i30/10338.htm DOI: http://dx.doi.org/10.3748/wjg.v20.i30.10338

INTRODUCTION
Helicobacter pylori (H. pylori) is a worldwide infection that affects millions of people. This infection is currently the main cause of gastritis, gastroduodenal ulcer disease, and gastric cancer. It was thirty years ago that H. pylori was discovered11 and twenty years ago that clarithromycin-
based triple therapy was established in clinical practice for the eradication of this infection[3]. Nowadays, the efficacy of triple therapy is seriously challenged in many parts of the world, where eradication rates have declined to unacceptably low levels, largely related to development of resistance to clarithromycin[3].

From a microbiological standpoint, the most rational way to overcome antibiotic resistance would be the use of a combination of drugs for which resistance does not appear to be a problem, so no clarithromycin-based regimens should be recommended in geographical areas with increasing clarithromycin resistance rates. In this context, bismuth-based quadruple therapy seems to be an attractive alternative treatment, especially in its most recent galenic formulation, bismuth subcitrate potassium, metronidazole, and tetracycline (BMT, sold under licence as Pylera®[6]. However, this logical scenario is not a realistic approach in many settings for clinical practice owing to a number of obstacles. H. pylori infection is mostly diagnosed and treated by gastroenterologists, instead of microbiologists, so the bulk of treatment is prescribed on an empirical basis and articles seldom report data on antibiotic resistance. Furthermore, bismuth salts are not widely available, many countries are currently experiencing a general unavailability of tetracycline and the launch of Pylera®, the three-in-one capsule decreasing pill burden and improving compliance for bismuth quadruple therapy, onto the market is being troublesome as well.

As such, several non-bismuth quadruple therapies have made a leap towards the front line to tackle H. pylori infection. Indeed, a formula has been elegantly developed to predict the outcome of these therapies according to antibiotic resistance rates[3]. The aim of this review is to summarize optimization tools and therapeutic innovations published over the last 5 years (August 2008-August 2013) aimed at increasing the efficacy of H. pylori clarithromycin-based first-line therapies.

**OPTIMIZING TRIPLE THERAPY**

**Increasing the length of duration**

It has been postulated that extending the duration of triple therapy up to 14 d might result in higher and acceptable cure rates. In fact, recent European guidelines state that extending the duration of proton pump inhibitor (PPI)-clarithromycin-containing triple therapies from 7 to 10-14 d improves the eradication success by about 5% and may be considered[8]. Conclusions from reviews and meta-analysis are mostly consistent with showing a clinical benefit of extending the duration[7,8], but other have drawn the opposite conclusion[9]. Similarly, recent articles have disclosed a benefit of prolonging the length of triple therapy in Greece[10] and Croatia[11], whereas others from South Korea[12] and Turkey[13] could not demonstrate an advantage for this strategy. As such, prolonging H. pylori triple therapy seems to increase eradication rates, albeit whether it represents a clinically useful strategy should be locally evaluated.

**Increasing acid-suppressive therapy**

H. pylori typically resides within the mucus layer of the human stomach, being the bulk of organisms attached to surface cells. Most importantly, a proportion of the organisms may remain in a non-replicative but viable state, which notably reduces the effectiveness of antibiotics that require microbial replication to kill the organisms, such as clarithromycin and amoxicillin[14]. This non-replicative state, which turns H. pylori phenotypically resistant, is more likely when gastric pH ranges from 5 to 6. Increasing the pH in this layer to 6 or 7 allows the bacteria to enter the replicative state where they become susceptible to amoxicillin and clarithromycin[15]. Therefore, the stronger acid suppression is, the higher the likelihood of antibiotic therapy success.

PPI therapy (omeprazole, lansoprazole, pantoprazole, rabeprazole, esomoprazole) are now widely used as the first-line acid inhibitors in eradication schemes. These drugs undergo hepatic metabolism via the CYP450 pathways and the isoforms CYP2C19 and, to a lesser extent, CYP3A4. There are interindividual differences in the activity of CYP2C19, which may impact PPIs pharmacokinetic behaviour and clinical efficacy[16,17]. Indeed, the phenotype of CYP2C19 is categorized into three groups: extensive or rapid metabolizer (EM), intermediate metabolizer (IM), and poor metabolizer (PM). The rate of CYP2C19 rapid metabolizers was proven to be higher in Europe and in North America (56%-81%), while the proportion was smaller (27%-38%) in the Asian population[18]. Significantly higher eradication rates of H. pylori have been observed in patients with poor and intermediate metabolizers phenotype compared to extensive metabolizers[19]. As such, initial genotyping for this enzyme would be ideal before H. pylori therapy, since higher dosage in extensive metabolizers is likely to improve the clinical efficacy of PPIs for H. pylori therapy. Seeing as this approach is unrealistic in clinical practice, it is conceivable that all patients, especially in Europe and North America, should receive high-dose PPI therapy to circumvent the high rate of PPI rapid metabolizers.

As for the different PPI available molecules, a recent meta-analysis disclosed that he efficacy of omeprazole- and lansoprazole- based first-line triple therapies at the standard doses was dependent on CYP2C19 genotype status, which appeared not to affect the efficacy of the regimens including rabeprazole[14]. In line with this finding, two other recent meta-analyses have demonstrated that esomoprazole and rabeprazole provide better overall H. pylori eradication rates, especially in CYP2C19 extensive metabolizers[19,20].

Finally, updated European Guidelines for H. pylori management have also recommended high-dose PPI therapy using new generation-PPIs, pointing out that increasing the dose of PPI from, for example, 20 mg omeprazole twice daily to 40 mg of esomeprazole or rabeprazole
Probiotics are live organisms or produced substances that are orally administrated, usually in addition to conventional antibiotic therapy for *H. pylori* infection. They may modulate the human microbiota, stimulate the immune response and directly compete with pathogenic bacteria, besides preventing antibiotic side effects. Indeed, probiotics have exhibited inhibitory activity against *H. pylori in vitro* and in vivo. At the present time, 6 meta-analyses have been published addressing the benefit of *Lactobacillus* and *Bifidobacterium* bovine lactoferrin, fermented milk-based probiotic formulations. The main results of these meta-analyses are summarized in Table 1. Available evidence collectively points towards a benefit of using probiotic for decreasing antibiotic-related side effects and, to a much lesser extent, increasing cure rates.

However, several considerations should be made before recommending probiotic in clinical practice. To begin with, they add complexity as they mean a fourth or, better, a fifth drug, their different concentrations, probiotic strain, dose and the length of duration. Further studies refining the most effective probiotic and the patient profile which will most benefit from probiotic supplementation are needed before a general recommendation in clinical practice can be made.

### Long-acting drugs

A recent study from Thailand reported 100% cure rates with 14-d high-dose PPI and long-acting clarithromycin. However, there were no clarithromycin-resistant *H. pylori* strains in the study, so these drugs need further validation in other geographical areas with different patterns of antibiotic resistance. At the present time, no study has evaluated this attractive hypothesis. The use of long-acting macrolides (azithromycin) has been recently associated with increasing *H. pylori* resistant to clarithromycin. Azithromycin is known to achieve high concentrations in the gastric mucus and gastric juice for several weeks after its administration, and this may lead to local subinhibitory concentrations and favour the selection of macrolide-resistant mutants, as above mentioned.

### NON-BISMUTH QUADRUPLE TREATMENTS

#### Sequential therapy

Sequential therapy was developed in Italy in 2000 as a replacement for triple therapy. It consists of 5 d of PPI therapy plus amoxicillin, followed by a further five days of PPI with two other antibiotics, usually clarithromycin and metronidazole. Up to 2008, the vast majority of studies on this therapeutic strategy had been conducted in Italy. In 2007, a randomized controlled trial from the same Italian authors showed a significant advantage of 10-day sequential over 10-d triple therapy (91% vs 78%, *P* = 0.002), being highly effective against clarithromycin-resistant strains. A pooled data analysis with Italian evidence showed promising eradication rates higher than 90%, even in patients with risk factors for triple therapy failure (clarithromycin or metronidazole resistance, non ulcer dyspepsia, smoking or the absence of the gene CagA). Indeed, several meta-analyses evidenced the advantage of sequential therapy over triple therapy. Accordingly, it was suggested in 2007 by the American College of Gastroenterology Guidelines and the European Maastricht Consensus (Maastricht III), as well as in 2009 by the Second Asia-Pacific Consensus Guidelines, that sequential therapy was a promising therapy, but it required further evaluation outside Italy, before a generalized change in first-line *H. pylori* treatment was recommended.

In 2010, a critical review of the evidence highlighted several concerns in previous meta-analyses, such as lack of validation outside of Italy, low quality studies or insufficient information on the effect on antibiotic resistant strains. In 2011, a large multicenter trial from Latin America showed no advantage of 10-d sequential therapy over 14-d triple therapy. In 2012 and 2013, an updated meta-analysis in children and two systematic reviews in adults dealing with sequential therapy have been published. The results are summarized in Table 2. From 2008 to 2012, cure rates of sequential therapy in studies conducted in Asia, Europe and Latin America remained significantly better than those of triple therapy, but mean eradication rates dramatically dropped by 15% compared to Italian trials before 2008. A recent multi-

---

**Table 1** Impact of adding probiotics to eradication therapy (mostly standard triple therapy) on eradication rates and side effects, evaluated in seven recent meta-analyses

| Ref. | Probiotic strains | Eradication rates | Side effects |
|------|------------------|------------------|-------------|
| Tong et al[24], 2007 | Lactobacillus and bifidobacteria | Significant increase | Significant reduction |
| Wang et al[25], 2013 | Lactofeinin | Significant increase | Significant reduction/ |
| Sachdeva et al[26], 2009 | Fermented milk | Significant increase | Significant reduction/ |
| Zou et al[27], 2009 | Lactobacillus | Significant increase | Significant reduction/ |
| Szajewska et al[28], 2010 | Saccharomyces boulardii | Significant increase | Significant reduction/ |

---
center study performed in Taiwan comparing 14-d sequential and triple therapy has definitely shown the limitations of sequential therapy, since the efficacy of this regimen was impaired by either clarithromycin and metronidazole resistance. Finally, a recent meta-analysis performed by the Italian creators of the sequential therapy showed a mean cure rate of 84% (95% CI: 82.1%-86.4%) for 10-d sequential therapy, being superior to seven day triple therapy, marginally superior to 10 d triple therapy but not superior to 14 d triple therapy. Right now, 10-d sequential therapy cannot be considered a good therapeutic option to overcome antibiotic resistance and its failure might be expected when dual resistant strains are > 5%.

The history of sequential therapy is a good one to learn. It was devised in 2000 in response to failure of triple therapy and was systematically compared to an “unfair comparator” (triple therapy), leading to a notable superiority of sequential therapy in meta-analyses. The treatment formula was not optimized and the detrimental effect of clarithromycin was noted, but not that of metronidazole. It took as a decade to understand microbiological drawbacks of sequential therapy and we cannot afford to try over the same stone when it comes to evaluating new H. pylori therapies.

Concomitant therapy

The concept of a “non-bismuth quadruple regimen” or “concomitant” regimen (the term used hereafter) consists of converting standard triple therapy to a quadruple therapy by the addition of 500 mg of metronidazole or tinidazole twice daily. In 1998, two groups of investigators, one in Germany and the other in Japan, proposed that a PPI, amoxicillin, clarithromycin, and nitroimidazole be given concurrently as a four-drug, three-antibiotic, non-bismuth-containing quadruple regimen. Despite the short duration of therapy (5 d on average), this approach provided, at that time, high cure rates (90% by intention-to-treat). After a few years of research, it fell into oblivion but resurfaced in 2010 as an alternative therapy to triple and sequential therapy. Since then, eleven studies have evaluated its effectiveness in Latin America, Asia (Thailand, South Korea, Japan, Taiwan, China), and Europe (Spain, Greece, Turkey and Italy). The results are disclosed in Figure 1, broken down by the length of therapy. Regardless of the duration of therapy, all studies showed intention-to-treat cure rates from 85% to 94%, with 4 exceptions (2 studies with a 5-d duration from Latin America (73.5%) and South Korea (80.7%); 1 study with a 14-d duration from Turkey (75%) and South Korea (80.8%)).

In the aforementioned article by Graham et al, the efficacy of 14-d concomitant therapy was not impaired by neither clarithromycin nor metronidazole isolated resistance, but it is expected to fall below 90% when the prevalence of dual clarithromycin-metronidazole resistant strains is > 15%. Therefore, the authors state that it cannot be recommended in settings where metronidazole resistance is greater than 60% (i.e., China, India, Iran or Central or South America) or in populations at high risk of dual resistance (i.e., following clarithromycin or metronidazole treatment failures). These recommendations are in agreement with suboptimal results in Latin America, South Korea and Turkey, where clarithromycin, but specially metronidazole, resistant H. pylori strains are

Table 2 Updated systematic reviews and meta-analyses (2008-2012) in children and adults comparing triple and sequential therapy for Helicobacter pylori infection

| Ref.       | Population and timeframe | n   | Triple therapy (95%CI) | Sequential therapy (95%CI) | P value |
|------------|--------------------------|-----|------------------------|----------------------------|---------|
| Horvath al, 2012 | Children 2005-2012       | 852 | 71% (66-75)            | 78% (73-82)               | 0.02    |
| Zullo et al, 2013 | Adults and children 2008-2012 | 2921 | 75.8% (73.5-78.1)   | 80.6% (78.5-82.7)         | 0.003   |
| Kate et al, 2013  | Adults and children 2008-2012 | 3247 | 71.4% (64-78)          | 81.7% (78-85)             | 0.02    |

Figure 1 Intention-to-treat cure rates of concomitant therapy over the last three years in studies conducted in Latin America, Asia and Europe, broken down by the duration of therapy. Studies with Intention-to-treat (ITT) < 85% are grey marked.
very prevalent. Likewise, they match with good to excellent results in Southern Europe and some Asian countries, where clarithromycin ranges from low (9%) to high (40%) figures, but metronidazole resistance remains in relatively low figures (<30%-40%).

**Sequential or concomitant therapy?**

Several studies have lately evaluated the efficacy of sequential and concomitant non-bismuth quadruple therapies against clarithromycin and metronidazole resistant strains. Georgopoulos et al. [71] nicely addressed this issue and we have adapted their results to exhibit the most promising results (Table 3). Concomitant and sequential therapies were successful against dual-resistant strains in 78% (18/23) and 33% (9/27) of the cases, respectively. Furthermore, a recent meta-analysis [72] comparing sequential and concomitant therapy has shown a significant advantage (OR = 1.51; 95%CI: 1.06-2.17) of concomitant therapy (Figure 2). Overall, solid evidence point towards concomitant therapy being a more reasonable therapeutic option in areas with a high incidence of clarithromycin and/or metronidazole resistance [73], even though we cannot miss the fact that it is expected to fail when the prevalence of dual clarithromycin-metronidazole resistant strains is > 15% [71].

**Hybrid therapy: A new kid on the block**

Hybrid sequential-concomitant regimen is a therapeutic innovation which includes a proton pump inhibitor (PPI) plus amoxicillin for 14 d, adding clarithromycin and a nitroimidazole for the final 7 d. In other words, it is a 7-d first dual phase (PPI + amoxicillin) followed by a 7-d quadruple phase (PPI + amoxicillin + clarithromycin + nitroimidazole). In 2011, a pilot study revealed outstanding cure rates [97% intention-to-treat (ITT) analysis] in three Taiwanese centers [74]. However, the rate of clarithromycin resistance in this region is low (7%) and required further validation in setting with different patterns of resistance. In 2012, hybrid therapy demonstrated to achieve significantly higher ITT cure rates over sequential therapy (89.5% vs 76.7%, P = 0.001) in Iran [74], a setting with high rates of antibiotic resistance. More recently, a noninferiority trial conducted in Spain and Italy [66] showed that both optimized concomitant and hybrid therapy achieved ITT eradication rates > 90% in settings with high rates of clarithromycin and metronidazole resistance. In this trial, hybrid therapy led to successful eradication in 1 out of 3 (33%) dual resistant strains. These are preliminary small numbers and definitely further research is warranted on this matter. Finally, a pilot study conducted in Italy [69] compared 5-d concomitant therapy, 10-d sequential therapy and 14-d hybrid therapy. Surprisingly, 5-d concomitant and 10-d sequential therapy achieved acceptable cure rates (> 90% on PP analysis), but not hybrid therapy (80%).

### CAN WE OPTIMIZE NON BISMUTH QUADRUPLE REGIMENS?

**Duration of therapy**

As for sequential therapy, 10-d sequential therapy was not superior to 14 d triple therapy, but 14-d sequential therapy proved to be superior to 14-d triple therapy [63,64]. Furthermore, metronidazole resistance undermines 10-d sequential therapy at 20% and 14-d sequential therapy at 30% [8].

Regarding concomitant therapy, meta-analyses have shown that the outcome is duration dependent [55,56]. In a recent head-to-head comparison in Thailand [57], 5-d proved unsatisfactory compared to 10-d concomitant therapy, besides 5-d concomitant therapy has also shown its failure in Latin America [46] and South Korea [48]. In the authors’ experience, 14-d concomitant achieved the best ITT results (92%) compared to studies evaluating 10-d concomitant therapy (86%-87%) [83,84].

**Acid suppression**

Both triple therapy and non-bismuth quadruple therapy contain amoxicillin and clarithromycin. As such, it is conceivable to speculate that the above mentioned data are valid for both therapies. Further studies are warranted to elucidate whether high-dose PPI therapy and either esomeprazole or rabeprazole show superiority for non-bismuth quadruple regimens (as it has been the case with triple therapy).

**Probiotics**

At the present time, data on the usefulness of probiotics for H. pylori eradication with quadruple therapies is anecdotal. Two recent trials [77,78] showed a reduction of side effects of probiotics combined with bismuth quadruple therapy and sequential therapy, but no increase in cure rates. No study has evaluated the addition of probiotics to concomitant or hybrid therapy.

### Table 3  Efficacy of sequential and concomitant therapy, with a duration of 10 to 14 d, on dual clarithromycin-metronidazole resistant Helicobacter pylori strains n (%)

| Ref. | Treatment duration (d) | Patients | Eradication rates |
|------|------------------------|---------|------------------|
| Wu et al [61], Thailand, 2010 | 10 | 4 | 3 (75%) |
| Huang et al [62], China, 2012 | 10 | 2 | 2 (100%) |
| Molina-Infante et al [63], Spain, 2012 | 10 | 4 | 3 (75%) |
| Molina-Infante et al [63], Spain-Italy, 2013 | 14 | 3 | 3 (100%) |
| Georgopoulos et al [64], Greece, 2013 | 10 | 10 | 7 (70%) |
| Total | | | 23 (18.78%) |

**Sequential therapy**

| Vaira et al [65], Italy, 2007 | 10 | 4 | 0 (0%) |
| Liou et al [66], Taiwan, 2013 | 14 | 8 | 3 (37%) |
| Wu et al [67], Thailand, 2010 | 10 | 3 | 1 (33%) |
| Huang et al [62], China, 2012 | 10 | 4 | 2 (50%) |
| Molina-Infante et al [63], Spain, 2012 | 10 | 5 | 3 (60%) |
| Romano et al [68], Italy, 2010 | 10 | 3 | 0 (0%) |
| Total | | | 27 (9.33%) |

Adapted from Georgopoulos et al [64], with permission.
Optimization of non-bismuth quadruple therapies (increasing antibiotic burden or increasing length of duration) adds complexity and might impact negatively on compliance with therapy. Regardless of the effect on cure rates, probiotics might be important to improve tolerance and compliance. On the contrary, they are “over-the-counter” drugs, therefore increasing costs, and add a fifth drug and may as well add complexity. More studies are required to refine the role of probiotics for these therapies and depict the patient characteristic that would benefit from coadjuvant probiotic supplementation.

### MISCELLANEOUS THERAPY: THE SUPER-OPTIMIZATION

Recently, an interesting pilot study from Colombia evaluating a “super-optimized” therapy, so called “miscellaneous”, has been published[79]. It consists of high-dose metronidazole (500 t.d.s) all along the therapy (15 d), dividing the remaining drugs into three 5-d phases: (1) First 5 d (lansoprazole 30 mg bid and amoxicillin 1 g qid); (2) Days 6 to 10: lansoprazole 30 mg qds; and (3) Days 11 to 15: lansoprazole 30 mg bid and clarithromycin 500 mg bid.

Therefore, this quadruple therapy has an optimized duration (15 d), high-dose PPI, high-dose metronidazole during 15 d trying to overcome the high rate of resistance (> 70%-80%) in Latin America and, of note, has a halfway period in which acid suppression is optimized (lansoprazole 120 mg/d) in order to avoid selection of non-replicative H. pylori strains. In this pilot study, miscellaneous therapy led to successful eradication rates [94% and 91% by per protocol (PP) and ITT, respectively], with a high rate of full compliants (96%) and acceptable side effects rate (55%), all of them mild.

Miscellaneous therapy is obviously burdened by its complexity and maybe its cost, depending on the geographical location, but provides an interesting and effective therapeutic tool in settings with metronidazole resistance > 40%, in which theoretically Maastricht IV precludes using metronidazole[5]. Definitely, more studies are awaited in this line of work to overcome antibiotic resistance.

### THERAPEUTIC ALGORITHM

Following this review, we propose a modified therapeutic algorithm for first-line H. pylori therapy (Figure 3). The success of treatments for infectious diseases is predictable if one knows the pattern of resistance and the effect of resistance on the regimens tested[5]. Clarithromycin resistance was the Achiles heel for triple therapy and now dual clarithromycin resistance rates is the Achiles heel for non-bismuth quadruple therapies. Non-bismuth sequential, hybrid and concomitant therapies are expected to fail if the rate of dual-resistant strains are > 5%, > 9% and > 15%, respectively. As such, eradication therapy should be “regionalized” depending on the prevalence of clarithromycin and metronidazole resistant strains. Currently, triple therapy should only be acceptable if eradication rates > 90% have been documented.

### TAKE-HOME MESSAGES

**Optimization tools for triple therapy**

1. Prolonging H. pylori triple therapy up to 14 d increases eradication rates by approximately 5%, albeit the clinical benefit of this strategy should be evaluated locally; (2) High-dose PPI therapy is recommended for triple therapy, especially in Europe and North America, where the prevalence of PPI extensive metabolizers is higher; (3) A discrete advantage of esomeprazole and rabeprazole over omeprazole, pantoprazole and lansoprazole has been shown in recent meta-analyses; and (4) Overall, probiotics seem to increase eradication rates and reduce antibiotic side-effects in adults, but they cannot be recommended for clinical practice yet.

**Sequential therapy**

Updated data in both children and adults point towards lower eradication rates than previously reported. Despite sequential therapy keeps on showing an advantage over triple therapy, unacceptable cure rates have been recently reported, without a therapeutic advantage over 14-d triple therapy. Its efficacy dramatically decreases upon the existence of metronidazole and dual clarithromycin and metronidazole resistant strains.
Concomitant therapy

Emerging evidence has shown concomitant therapy to be an effective therapy (> 90% cure rates) in Southern Europe and some Asian countries (Thailand, Taiwan, Japan, China). Compared to sequential therapy, its efficacy is less impaired by clarithromycin and metronidazole resistant strains and therefore seems to be the best replacement for triple therapy. However, it has been proven unsuccessful in Turkey and South Korea, where both clarithromycin and specially metronidazole, resistance rates are notably high.

Hybrid therapy

It is a therapeutic innovation combining sequential and concomitant therapy, with a 7-d first dual phase (PPI + amoxicillin) followed by a 7-d quadruple phase (PPI + amoxicillin + clarithromycin + nitroimidazole). It has currently demonstrated an advantage over sequential therapy and not to be inferior to concomitant therapy, although further research is not warranted.

REFERENCES

1 Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311-1315 [PMID: 6143025 DOI: 10.1016/S0140-6736(84)91816-6]
2 Bazzoli F, Zagari RM, Fossi S, Pozzato P, Roda A, Roda E. Efficacy and tolerability of a short-term low-dose triple therapy for eradication of Helicobacter pylori. Gastroenterology 1993; 104: 40A (Abstract).
3 Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-1153 [PMID: 20525969 DOI: 10.1136/gut.2009.192757]
4 Megraud F. The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy. Therap Adv Gastroenterol 2012; 5: 103-109 [PMID: 22423259 DOI: 10.1177/1756283X11432494]
5 Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12: 177-86.e3; Discussion e12-3 [PMID: 23751282 DOI: 10.1016/j.cgh.2013.05.028]
6 Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection—The Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-30284]
7 Calvet X, García N, López T, Gisbert JP, Gené E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxicillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 663-669 [PMID: 10702124]
8 Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol 2003; 17 Suppl B: 36B-40B [PMID: 12845349]
9 Fuccio L, Minardi ME, Zagari RM, Di Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007; 147: 553-562 [PMID: 1798394]
10 Karatapanis S, Georgopoulos SD, Papastergiou V, Skorda L, Papantoniou N, Lisgos P, Kouvidou C, Fragkou P, Mentis A. “1, 10 and 14-days rabeprazole-based standard triple therapies for H. pylori eradication: are they still effective? A randomized trial”. Acta Gastroenterol Belg 2011; 74: 407-412 [PMID: 22103045]
11 Filipec Kanizaj T, Katicic M, Skurla B, Ticak M, Plecko V, Kalenic S. Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens. Helicobacter 2009; 14: 29-35 [PMID: 19191893 DOI: 10.1111/j.1523-5378.2009.00656.x]
12 Choi HS, Chun HJ, Park SH, Keum B, Seo YS, Kim YS, Jeen YT, Um SH, Lee HS, Kim CD, Ryu HS. Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter py-
lori infection. World J Gastroenterol 2012; 18: 2377-2382 [PMID: 22654429 DOI: 10.3748/wjg.v18.i19.2377]

13 Usta Y, Saltik-Temizel IN, Demir H, Uslu N, Ozen H, Gur-akan F, Yuce A. Comparison of short- and long-term treat-
ment protocols and the results of the follow-up study in children with Helicobacter pylori infection. J Gastro-
troenterol 2008; 43: 429-433 [PMID: 18600386 DOI: 10.1007/
S00355-008-1881-7]

14 Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic poly-
morphisms on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2008; 20: 153-167 [PMID: 19580817]

15 Seranno D, Torrado S, Torrado-Santiago S, Gisbert JP. The influence of CYP2C19 genetic polymorphism on the phar-
macokinetics/- pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments. Curr Drug Metab 2012; 13: 1303-1312 [PMID: 22493986]

16 Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Nakamura M, Tazuma S. Acid-suppressive effects of rabeprazole, 
omeprazole, and lanoseprazole at reduced and standard dos-
es: a crossover comparative study in homoeogenic extensive 
metabolizers of cytochrome P450 2C19. Clin Pharmacol Ther 
2009; 79: 144-152 [PMID: 16413249]

17 Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 
2004; 95: 2-8 [PMID: 15425659]

18 Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z, 
Zhang G. Effect of CYP2C19 genetic polymorphisms on the 
efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helico-
bacter 2008; 13: 532-541 [PMID: 19166419 DOI: 10.1111/
J.1523-5378.2008.00643.x]

19 McNicholl AG, Linares PM, Nysson OP, Calvet X, Gisbert 
JP. Meta-analysis: esomeprazole or rabeprazole vs. first-
generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36: 414-425 
[PMID: 22803691 DOI: 10.1111/j.1365-2036.2012.05211.x]

20 Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 
loss-of-function variants on the eradication of H. pylori in 
fected in patients treated with proton pump inhibitor-based 
triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS One 2013; 8: e62162 [PMID: 23646118 
DOI: 10.1371/journal.pone.0062162]

21 Vitor JM, Vale FF. Alternative therapies for Helicobacter pylori: probiotics and phytomedicine.EMS Immunol Med 
Microb 2011; 63: 153-164 [PMID: 22077218 DOI: 10.1111/
j.1574-695X.2011.00865.x]

22 Aiba Y, Suzuki N, Kabir AM, Takagi A, Koga Y. Lactic ac-
id-mediated suppression of Helicobacter pylori by the oral 
administration of Lactobacillus salivarius as a probiotic in 
a gnotobiotic murine model. Am J Gastroenterol 1998; 93: 
2097-2101 [PMID: 9820379]

23 Pinchuk IV, Bressolier P, Verneuil B, Fenet B, Sorokulova 
IB, Mégraud F, Urday MC. In vitro anti-Helicobacter pylori 
activity of the probiotic strain Bacillus subtilis 3 is due to se-
cretion of antibiotics. Antimicrob Agents Chemother 2001; 45: 
3156-3161 [PMID: 11600371]

24 Tong JL, Ran ZH, Shan J, Zhang CX, Xiao SD. Meta-
analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007; 25: 
155-168 [PMID: 17229240]

25 Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy 
and safety of Lactobacillus-containing and Bifidobacterium-
containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol 2013; 47: 25-32 
[PMID: 23090045 DOI: 10.1097/MCG.0b013e31826e66fe]

26 Sachdeva A, Nagpal J. Meta-analysis: efficacy of bovine 
lactoferrin in Helicobacter pylori eradication. Aliment Phar-
cmacol Ther 2009; 29: 720-730 [PMID: 19183156]

27 Zou J, Dong J, Yu XF. Meta-analysis: the effect of supple-
mentation with lactoferrin on eradication rates and adverse 
events during Helicobacter pylori eradication therapy. Helicobacter 2009; 14: 119-127 [PMID: 19269339 DOI: 10.1111/
J.1523-5378.2009.00668.x]

28 Sachdeva A, Nagpal J. Effect of fermented milk-based pro-
biotic preparations on Helicobacter pylori eradication: a sys-
temic review and meta-analysis of randomized-controlled 
trials. Eur J Gastroenterol Hepatol 2009; 21: 45-53 [PMID: 
19060631 DOI: 10.1097/MEG.0b013e3280d08ed]

29 Zou J, Dong J, Yu X. Meta-analysis: Lactobacillus containing 
quadrupe therapy versus standard triple first-line therapy for 
Helicobacter pylori eradication. Helicobacter 2009; 14: 
97-107 [PMID: 19751434 DOI: 10.1111/j.1523-5378.2009.00716]

30 Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: 
the effects of Saccharomyces boulardii supplementation on 
Helicobacter pylori eradication rates and side effects during 
treatment. Aliment Pharmacol Ther 2010, 32: 1069-1079 [PMID: 
20139671 DOI: 10.1111/j.1365-2036.2010.04457.x]
Molina-Infante J et al. Optimizing clarithromycin-based H. pylori therapy

41 Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. *Ann Intern Med* 2008; 148: 929-931 [PMID: 18490667]

42 Tong JJ, Sun J, Shen J, Xiao SD. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. *J Clin Pharm Ther* 2009; 34: 41-53 [PMID: 19125902 DOI: 10.1111/j.1365-2710.2008.00969.x]

43 Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. *Am J Gastroenterol* 2009; 104: 3069-379; quiz 1080 [PMID: 19844205 DOI: 10.1038/ajg.2009.555]

44 Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. *Am J Gastroenterol* 2007; 102: 1808-1825 [PMID: 17686775]

45 Mallertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. *Gut* 2007; 56: 772-781 [PMID: 1710018]

46 Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. *J Gastroenterol Hepatol* 2009; 24: 1587-1600 [PMID: 19788600 DOI: 10.1111/j.1440-1746.2009.04952.x]

47 Gisbert JP, Calvet X, O’Connor A, Mégraud F, O’Morain C. Nonbismuth quadruple (concomitant) therapy versus standard triple therapy for Helicobacter pylori eradication: a randomized pilot study. *Helicobacter* 2013; 18: 180-186 [PMID: 2330583]

48 Yanai A, Sakamoto K, Akanuma M, Ogura K, Maeda S. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan. *World J Gastrointest Pharmacol Ther* 2012; 3: 1-6 [PMID: 22487844 DOI: 10.4292/wjgpt.v3.i1.1]

49 Lim JH, Lee DH, Choi C, Lee ST, Kim N, Jeong SH, Kim JW, Hwang JH, Park YS, Lee SH, Chin MJ, Jo HJ, Jang ES, Song IS, Jung HC. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: A randomized study in Japan. *Helicobacter* 2013; 18: 180-186 [PMID: 2330583]

50 Okada M, Oki K, Shiriotani T, Seo M, Okabe N, Maeda K, Nishimura H, Okuhama K, Oda K. A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. *J Gastroenterol Hepatol* 1998; 13: 32-37 [PMID: 9546119]

51 Opekun AR, Kuo CH, Lee YC, Chang LL, Wang TH, Chen YH, Wang WM, Wu DC, Kuo FC. Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication. *J Dig Dis* 2012; 13: 232-238 [PMID: 22355059 DOI: 10.1111/j.1751-2802.2012.00575.x]

52 McNeill AG, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducros J, Calvet X, de la Coba C, Montoro M, Bory F, Perez-Aisa A, Forne M, Gisbert JP. Optimised randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. *Gut* 2014; 63: 244-249 [PMID: 2366990]

53 Molina-Infante J, Romano M, Fernandez-Bermejo M, Fedrico A, Gravina AG, Pozzato L, Garcia-Abadia E, Vinagre-Rodriguez G, Martinez-Alcala C, Hernandez-Alonso M, Gonzalez-Garcia G, Mateos-Rodriguez JM, Fernandez-Bermejo M, Gisbert JP. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. *Helicobacter* 2012; 17: 269-276 [PMID: 22795926 DOI: 10.1111/j.1523-5378.2012.00947.x]

54 Treiber G, Ammon S, Schneider E, Klotz U. Amoxicillin/ metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. *Helicobacter* 1998; 3: 54-58 [PMID: 9546119]

55 McNeill AG, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducros J, Calvet X, de la Coba C, Montoro M, Bory F, Perez-Aisa A, Forne M, Gisbert JP. Optimised randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. *Gut* 2014; 63: 244-249 [PMID: 2366990]
area. *Helicobacter* 2013; 18: 459-467 [PMID: 23714140 DOI: 10.1111/hel.12062]

67 Georgopoulos S, Papastergiou V, Xirouchakis E, Laudi F, Papantoniou N, Lisgos P, Spiliadi C, Fragou P, Skorda L, Karatapanis S. Evaluation of a four-drug, three-antibiotic, non-bismuth-containing “concomitant” therapy as first-line Helicobacter pylori eradication regimen in Greece. *Helicobacter* 2012; 17: 49-53 [PMID: 22221616 DOI: 10.1111/j.1523-5378.2011.00911.x]

68 Toros AB, Ince AT, Kesici B, Saglam M, Polat Z, Uygun A. A new modified concomitant therapy for Helicobacter pylori eradication in Turkey. *Helicobacter* 2011; 16: 49-53 [PMID: 21585608 DOI: 10.1111/j.1523-5378.2011.00823.x]

69 De Francesco V, Hassan C, Ridola L, Giorgio F, Ierardi E, Zullo A. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. *J Med Microbiol* 2014; 63: 748-752 [PMID: 24586031 DOI: 10.1099/jmm.0.072322-0]

70 Romano M, Cuomo A, Gravina AG, Miranda A, Iovene MR, Tiso A, Sica M, Rocco A, Salerno R, Marmo R, Federico A, Nardone G. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. *Gut* 2010; 59: 1465-1470 [PMID: 20947881 DOI: 10.1136/gut.2010.215350]

71 Georgopoulos SD, Xirouchakis E, Mentis A. Is there a nonbismuth quadruple therapy that can reliably overcome bacterial resistance? *Gastroenterology* 2013; 145: 1496-1497 [PMID: 24409502]

72 McNicholl AG, Nyssen OP, Gisbert JP. Sequential and Concomitant Treatments in H. pylori Eradication: A Network Meta-Analysis. *Gastroenterology* 2014; 146 Suppl 1: S-393

73 Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. *Helicobacter* 2011; 16: 139-145 [PMID: 21435092 DOI: 10.1111/j.1523-5378.2011.00828.x]

74 Sardarian H, Fakheri H, Hosseini V, Taghvaei T, Maleki I, Mokhtare M. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. *Helicobacter* 2013; 18: 129-134 [PMID: 23121338 DOI: 10.1111/hel.1201]

75 Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. *Helicobacter* 2009; 14: 109-118 [PMID: 19296338 DOI: 10.1111/j.1523-5378.2009.00671]

76 Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. *Aliment Pharmacol Ther* 2011; 34: 604-617 [PMID: 21745241 DOI: 10.1111/j.1365-2036.2011.04770.x]

77 Shavakhi A, Tabesh E, Yaghoutkar A, Hashemi H, Tabesh F, Khodadoostan M, Minakari M, Shavakhi S, Gholamrezaei A. The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for Helicobacter pylori infection: a randomized placebo-controlled triple-blind study. *Helicobacter* 2013; 18: 280-284 [PMID: 23433200 DOI: 10.1111/hel.12047]

78 Manfredi M, Bizzarri B, Saccheri RI, Maccari S, Calabrese L, Fabbian F, De’Angelis GL. Helicobacter pylori infection in clinical practice: probiotics and a combination of probiotics + lactoferrin improve compliance, but not eradication, in sequential therapy. *Helicobacter* 2012; 17: 254-263 [PMID: 22759324 DOI: 10.1111/j.1523-5378.2012.00944.x]

79 Sierra F, Forero JD, Rey M, Botero ML, Cárdenas A. Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. *Aliment Pharmacol Ther* 2013; 37: 1165-1171 [PMID: 23656465 DOI: 10.1111/apt.12329]

P- Reviewer: Balaban YH, Mansour-Ghanaei F, Paulssen EJ, Sari YS
S- Editor: Wen LL  L- Editor: A E- Editor: Ma S
